NR4A2 and neoplasm: To restrict A1R expression to the tumor site we therefore utilized a CRISPR knock-in approach to drive A1R expression under the control of the endogenous NR4A2 promoter, which we have previously demonstrated to be highly tumor-restricted in its transcriptional activity.